Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan

Published on Nov 1, 2019in Journal of Viral Hepatitis3.561
· DOI :10.1111/JVH.13170
Hiroki Ikeda12
Estimated H-index: 12
(St. Marianna University School of Medicine),
Tsunamasa Watanabe18
Estimated H-index: 18
(St. Marianna University School of Medicine)
+ 36 AuthorsTakashi Kumada60
Estimated H-index: 60
: Based on high efficacy and safety demonstrated in clinical trials, treatment with glecaprevir/pibrentasvir (G/P) for 8 weeks is recommended for hepatitis C virus (HCV)-infected patients who are direct-acting antiviral (DAA) naive, genotype 1 or 2, and noncirrhotic. The aim of this study was to validate real-world experience with 8-week G/P treatment in Japan. We conducted a prospective observational cohort study in 554 patients who underwent 8-week treatment from among 1,022 patients who initiated G/P therapy. The majority (54.5%) were male, with a median age of 66 years, and HCV genotype distribution was genotype 1, 43.8%; genotype 2, 55.3%; and mixed subtype, 0.9%. Overall, the sustained virologic response rate at 12 weeks (SVR12) was 92.8% (530/571) in the intention-to-treat population and 99.3% (526/530) in the per-protocol population. The SVR12 rates by subgroups were as follows: subtype 1a, 100% (6/6); 1b, 100% (189/189); 2a, 99.3% (150/151); 2b, 99.0% (103/104); and mixed subtype, 50% (2/4). Among four patients with virologic failure following 8-week treatment with G/P, none had baseline polymorphisms or treatment-emergent amino acid substitutions in NS3. However, 2 of 4 patients with virologic failure had treatment-emergent amino acid substitutions in NS5A. Adverse events (AEs) were reported in 21.5% of patients and 1.2% of patients discontinued due to drug-related AEs. In conclusion, G/P treatment for 8 weeks was safe and effective for DAA-naive noncirrhotic genotype 1 or 2 patients in a real-world clinical setting in Japan.
📖 Papers frequently viewed together
11 Authors (Young Joo Park, ..., Mong Cho)
146 Citations
6 Citations
#1Roberta D'Ambrosio (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 23
#2Luisa PasuloH-Index: 13
Last. Stefano FagiuoliH-Index: 54
view all 42 authors...
Background and Aims The efficacy and safety of glecaprevir/pibrentasvir (G/P) for patients infected with hepatitis C virus (HCV) have only been investigated in clinical trials, with no real-world data currently available. The aim of our study was to investigate the effectiveness and safety of G/P in a real-world setting. Methods All patients with HCV consecutively starting G/P between October 2017 and January 2018 within the NAVIGATORE-Lombardia Network were analyzed. G/P was administered accord...
81 CitationsSource
#1Raymond T. ChungH-Index: 113
#2Marc G. GhanyH-Index: 70
Last. Kimberly A. WorkowskiH-Index: 46
view all 31 authors...
: Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based process for the expeditious formulation and dissemination of evidence-based recommendations. Launched in 2014, the hepatitis C virus (HCV) guidance website undergoes periodic updates as necessitated by availability of new therapeutic agents and/or...
317 CitationsSource
#1Preethi Krishnan (AbbVie)H-Index: 24
#2Tami Pilot-Matias (AbbVie)H-Index: 52
Last. Christine A. Collins (AbbVie)H-Index: 29
view all 13 authors...
: Over 2,200 patients infected with hepatitis C virus (HCV) genotypes (GT) 1 to 6, with or without cirrhosis, who were treatment naive or experienced to interferon, ribavirin, and/or sofosbuvir were treated with glecaprevir/pibrentasvir for 8, 12, or 16 weeks in eight registrational phase 2 and 3 clinical studies. High rates of sustained virologic response at 12 weeks postdosing (SVR12) were achieved with a <1% virologic failure (VF) rate. The prevalence of baseline polymorphisms (BPs) in NS3 at...
47 CitationsSource
#2Karine Lacombe (UPMC: Pierre-and-Marie-Curie University)H-Index: 32
Last. Mark S. Sulkowski (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 98
view all 22 authors...
Background: Once-daily glecaprevir coformulated with pibrentasvir (glecaprevir/pibrentasvir) demonstrated high rates of sustained virologic response 12 weeks after treatment (SVR12) in patients with hepatitis C virus (HCV) genotype 1-6 infection. This phase 3 study evaluated the efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV genotype 1-6 and human immunodeficiency virus type 1 (HIV-1) coinfection, including patients with compensated cirrhosis. Methods: EXPEDITION-2 ...
86 CitationsSource
#1Massimo PuotiH-Index: 63
#2Graham R. Foster (QMUL: Queen Mary University of London)H-Index: 79
Last. Federico J. Mensa (AbbVie)H-Index: 20
view all 19 authors...
Background & Aims Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection. In nine phase II or III clinical trials, G/P therapy achieved rates of sustained virologic response 12 weeks after treatment (SVR12) of 93–100% across all six major HCV genotypes (GTs). An integrated efficacy analysis of 8- and 12-week G/P therapy in patients without cirrhosis with HCV GT 1–6 infection was performed. Me...
84 CitationsSource
#1Jean-Michel PawlotskyH-Index: 109
#2Alessio AghemoH-Index: 40
Last. Christophe SarrazinH-Index: 1
view all 6 authors...
Summary Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of...
1,968 CitationsSource
#1Kazuaki Chayama (Hiroshima University)H-Index: 124
#2Fumitaka SuzukiH-Index: 67
Last. Hiromitsu KumadaH-Index: 89
view all 22 authors...
Background The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir (G/P), demonstrated high rates of sustained virologic response (SVR) in phase 2 and 3 studies outside Japan.
81 CitationsSource
#1Fred Poordad (University of Texas at Austin)H-Index: 63
#2Stanislas PolH-Index: 102
Last. Federico J. Mensa (AbbVie)H-Index: 20
view all 20 authors...
Methods: MAGELLAN-1 Part 2 was a randomized, open-label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and prior virologic failure on at least one NS3/4A protease and/or NS5A inhibitor-containing therapy. Patients with compensated liver disease, with or without cirrhosis, and HCV genotype (GT) 1, 4, 5, or 6 were randomized 1:1 to receive 12 or 16 weeks of G/P. The primary endpoint was susta...
97 CitationsSource
#1Hidenori ToyodaH-Index: 63
#2Kazuaki Chayama (Hiroshima University)H-Index: 124
Last. Hiromitsu KumadaH-Index: 89
view all 22 authors...
Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once-daily, all oral, ribavirin (RBV)-free, direct-acting antiviral regimen, was evaluated for safety and efficacy in hepatitis C virus genotype 2 (GT2)–infected Japanese patients, including those with compensated cirrhosis. CERTAIN-2 is a phase 3, open-label, multicenter study assessing the safety and efficacy of G/P (300/120 mg) once daily in treatment-naive a...
72 CitationsSource
#1David L. WylesH-Index: 36
#2Fred PoordadH-Index: 63
Last. Federico J. Mensa (AbbVie)H-Index: 20
view all 18 authors...
This study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options. SURVEYOR-II, Part 3 was a partially randomized, open-label, multicenter, phase 3 study. Treatment-experienced (prior interferon or pegylated interferon ± ribavirin or sofosbuvir plus ribavirin ± pegylated interferon therapy...
96 CitationsSource
Cited By11
#1Masanori Atsukawa (Nippon Medical School)H-Index: 20
#2Akihito Tsubota (Jikei University School of Medicine)H-Index: 44
Last. Tsuyoshi Ishikawa (Yamaguchi University)H-Index: 17
view all 28 authors...
Evaluating liver fibrosis is crucial for disease severity assessment, treatment decisions, and hepatocarcinogenic risk prediction among patients with chronic hepatitis C. In this retrospective multicenter study, we aimed to construct a novel model formula to predict cirrhosis. A total of 749 patients were randomly allocated to training and validation sets at a ratio of 2:1. Liver stiffness measurement (LSM) was made via transient elastography using FibroScan. Patients with LSM ≥12.5 kPa were reg...
#1Yeo Wool Kang (Dong-a University)
#2Yang Hyun Baek (Dong-a University)
view all 12 authors...
BACKGROUND The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was to assess the real-world effectiveness and safety of DAA regimens for the treatment of patients with chronic HCV genotype 2. METHODS We retrospectively analyzed the clinical data of patients treated with sofosbuvir plus ribavirin (SOF + RBV) or glecaprevir/pibrentasvir (G/P) for chronic HCV genotype 2 infection a...
#1Xiaoqing LiuH-Index: 1
#2Peng Hu (LMB: Laboratory of Molecular Biology)H-Index: 25
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease, including decompensated cirrhosis and hepatocellular carcinoma. Over 95% of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved for patients with HCV infection. The glecaprevir/pibrentasvir (G/P) regimen has some features that distinguish it from others and is the only 8-week regimen approved for treatment-naive patients and ...
2 CitationsSource
#1Wei-Ming Chen (CNU: Chia Nan University of Pharmacy and Science)H-Index: 2
#2Kuo-Liang Wei (Memorial Hospital of South Bend)H-Index: 5
Last. Chao-Hung Hung (CGU: Chang Gung University)H-Index: 46
view all 11 authors...
Background The real-world data of glecaprevir/pibrentasvir (GLE/PIB) therapy for patients with chronic hepatitis C virus (HCV) genotype 2 infection remained limited. We aimed to evaluate the possible predictors of virological failure and side effects of GLE/PIB therapy for chronic genotype 2 HCV-infected patients in a real-world setting. Methods A total of 326 compensated HCV genotype 2 patients treated with GLE/PIB 12 weeks for cirrhotic patients (n = 56) and 8 weeks for non-cirrhotic patients ...
#1Masanori Atsukawa (Nippon Medical School)H-Index: 20
#2Akihito Tsubota (Jikei University School of Medicine)H-Index: 44
Last. Toru IshikawaH-Index: 20
view all 42 authors...
Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings. We aimed to evaluate the safety and efficacy of sofosbuvir/velpatasvir for decompensated cirrhotic patients with genotypes 1 and 2 in real-world clinical practice. A prospective, multicenter study of 12-week sofosbuvir/velpatasvir was conducted for patients with decompensated cirrhosis at 33 institutions. T...
4 CitationsSource
#1Hsu-Heng YenH-Index: 9
#2Pei-Yuan SuH-Index: 3
Last. Kun-Ching ChouH-Index: 3
view all 10 authors...
INTRODUCTION Chronic hepatitis C virus (HCV) infection is increasingly observed in patients with renal disease. With the introduction of glecaprevir/pibrentasvir (GLE/PIB) as a pan-genotype therapy for HCV, treatment efficacy is expected to rise. MATERIALS AND METHODS This retrospective study evaluated the efficacy and safety of GLE/PIB treatment in adults with HCV infection and end-stage renal disease (ESRD). The primary end point was sustained virological response (SVR) observed 12 weeks after...
4 CitationsSource
#1Hidenori ToyodaH-Index: 63
#2Masanori Atsukawa (Nippon Medical School)H-Index: 20
Last. Takeshi OkanoueH-Index: 67
view all 40 authors...
BACKGROUND AND AIM: The presence of cirrhosis is an important factor for the management of patients with hepatitis C virus (HCV) infection and it determines the duration of treatment for HCV with the direct-acting antiviral (DAA) regimen of glecaprevir (GLE) and pibrentasvir (PIB), that is, 8 or 12 weeks, if patients do not have a history of DAA failure. However, in real-world settings, determination of cirrhosis depends on the discretion of the attending hepatologists, and it is unclear whether...
1 CitationsSource
#1Ming-Lung Yu (KMU: Kaohsiung Medical University)H-Index: 60
#2Pei-Jer Chen (NTU: National Taiwan University)H-Index: 117
Last. Wan-Long Chuang (KMU: Kaohsiung Medical University)H-Index: 61
view all 14 authors...
Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been reported in Taiwan, especially in high-risk populations including people who inject drugs (PWID) and patients requiring dialysis. Besides, certain populations merit special considerations due to suboptimal outcome, potential drug–drug interaction, or possible side effect. Therefore, in the second part of this 2-part ...
27 CitationsSource
#1Kazuki Ohya (Hiroshima University)H-Index: 5
#2Michio Imamura (Hiroshima University)H-Index: 44
Last. Kazuaki Chayama (Hiroshima University)H-Index: 124
view all 16 authors...
Although NS3/4 protease inhibitor glecaprevir (GLE) plus NS5A inhibitor pibrentasvir (PIB) therapy has a high efficacy for chronic hepatitis C virus (HCV)-infected patients with hemodialysis, some patients fail to respond to the therapy. Here, we report a hemodialysis genotype 2 HCV-infected patient who achieved sustained virological response (SVR) by 12 weeks of GLE/PIB therapy after failing to respond to 8 weeks of GLE/PIB therapy. A 44-year-old man with chronic genotype 2a HCV-infection witho...
2 CitationsSource
Direct-acting anti-virals (DAAs) have markedly improved the effectiveness of anti-viral therapy for chronic hepatitis C (CHC) patients. In a phase III trial in Japan, treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir (G/P) resulted in a small number of patients with refractory factors. We aimed to evaluate the effectiveness and safety of G/P, especially among patients with these refractory factors, and the influence of these factors on treatment. In a p...
7 CitationsSource